How can bullous lichen planus be distinguished from lichen planus–bullous pemphigoid overlap, and what are the recommended diagnostic steps and management strategies for each?

Differential Diagnosis and Management of Bullous Lichen Planus vs. Lichen Planus-Bullous Pemphigoid Overlap

The critical distinction between bullous lichen planus (BLP) and lichen planus pemphigoides (LPP) is made by direct immunofluorescence (DIF): BLP is DIF-negative while LPP shows linear IgG and/or C3 deposits at the dermoepidermal junction, identical to bullous pemphigoid. 1, 2

Key Distinguishing Features

Clinical Presentation

Bullous Lichen Planus:

• Bullae arise within or directly on pre-existing lichenoid papules/plaques 3
• More localized distribution
• Typical violaceous, polygonal, flat-topped papules with Wickham's striae present
• Responds to topical corticosteroids or dapsone alone 4
• Shorter, self-limited course 1

Lichen Planus Pemphigoides (LP-BP Overlap):

• Bullae develop on normal-appearing or erythematous skin separate from lichenoid lesions 5, 2
• More widespread, generalized blistering 1
• Concurrent but distinct lichen planus lesions present elsewhere
• Requires systemic corticosteroids for control 1
• Prolonged, chronic course similar to bullous pemphigoid 1

Histopathology

BLP shows:

• Subepidermal bullae with severe basal cell hydropic degeneration
• Classic lichenoid interface dermatitis features (band-like lymphocytic infiltrate, saw-tooth rete ridges)
• Bullae form as direct consequence of extensive lichenoid inflammation destroying the dermoepidermal junction 3, 1

LPP shows:

• Subepidermal bullae resembling bullous pemphigoid
• Often more neutrophils than typical BP 1
• May have separate areas showing lichenoid changes, but bulla formation is not directly related to lichenoid inflammation 5

Immunopathology (The Definitive Test)

BLP:

• DIF: Negative (no immunoreactants at basement membrane zone) 1, 2
• May show cytoid bodies with IgM in papillary dermis (nonspecific)
• Indirect immunofluorescence: May show antigranulosum antibodies (not pathogenic) 4

LPP:

• DIF: Positive - linear IgG and/or C3 at dermoepidermal junction 1, 5, 2
• Identical pattern to bullous pemphigoid
• ELISA: Anti-BP180 (type XVII collagen) antibodies positive 2
• Salt-split skin: IgG binds to epidermal (roof) side 6

Diagnostic Algorithm

1. Obtain two biopsies:

   • Fresh bulla for H&E (in formalin)
   • Perilesional skin for DIF (in Michel's medium or fresh frozen)

2. If subepidermal bulla on histology:

   • Perform DIF immediately
   • Negative DIF = BLP (represents "hyper-reactive lichen planus") 3
   • Positive DIF (linear IgG/C3) = LPP (autoimmune disease) 1, 2

3. If DIF positive, confirm with:

   • Anti-BP180 ELISA 6, 2
   • Salt-split skin indirect immunofluorescence (epidermal binding) 6

Critical pitfall: Do not rely on clinical appearance alone—bullae can arise on normal skin in both conditions if inflammation is severe enough. DIF is mandatory for accurate diagnosis 2.

Management

Bullous Lichen Planus

First-line:

• Superpotent topical corticosteroids (clobetasol propionate 0.05%) applied to affected areas 3
• Dapsone 50-100 mg daily (check G6PD first) 3, 4

Second-line:

• Short course oral prednisone 0.5-1 mg/kg if extensive 3
• Acitretin for refractory cases 3

Expected course: Self-limited, responds well to topical therapy alone in most cases 1

Lichen Planus Pemphigoides (LP-BP Overlap)

Treat as bullous pemphigoid following European Dermatology Forum guidelines 6:

For extensive disease:

• First-line: Clobetasol propionate 0.05% cream 30-40 g daily (whole body except face) OR oral prednisone 0.5-1 mg/kg daily 6
• Continue until disease control (no new lesions, established lesions healing)
• Taper after 15 days of disease control 6

Tapering schedule for topical:

• Month 1: Daily application
• Month 2: Every 2 days
• Month 3: Twice weekly
• Month 4+: Once weekly for 8 months maintenance 6

Adjunctive immunosuppression if inadequate response:

• Azathioprine (check TPMT) 6
• Mycophenolate mofetil 6
• Dapsone (less effective than in BLP) 6

Pre-treatment workup (per Table 2): CBC, metabolic panel, LFTs, hepatitis B/C serology if planning immunosuppression, G6PD if considering dapsone 6

Expected course: Chronic disease requiring prolonged therapy, similar to bullous pemphigoid 1

Pathophysiologic Distinction

BLP represents the extreme consequence of lichenoid inflammation mechanically disrupting the dermoepidermal junction—it is not autoimmune 1, 2. The bullae form because severe basal keratinocyte destruction creates cleavage planes.

LPP is a true autoimmune blistering disease where lichenoid inflammation exposes basement membrane antigens (particularly BP180/type XVII collagen), breaking immune tolerance and triggering pathogenic autoantibody production 5, 2. The blistering mechanism is identical to bullous pemphigoid.

This fundamental difference explains why BLP responds to anti-inflammatory therapy alone while LPP requires immunosuppression targeting autoantibody production 1, 2.